PROTEOSTASIS THERAPEUTICS, INC. License Agreements
10 Contracts & Agreements
- Fourth Amendment to Option and License Agreement (CD27), dated as of December 14, 2023, by and between Gigagen, Inc. and Kineta, Inc (Filed With SEC on December 15, 2023)
- Second Amendment to Option and License Agreement (CD27), dated as of December 21, 2022, by and between Gigagen, Inc. and the Company (Filed With SEC on August 11, 2023)
- Third Amendment to Option and License Agreement (CD27), dated as of May 25, 2023, by and between Gigagen, Inc. and Kineta, Inc (Filed With SEC on May 30, 2023)
- Second Amendment to Option and License Agreement (VISTA), dated as of May 25, 2023, by and between Gigagen, Inc. and Kineta, Inc (Filed With SEC on May 30, 2023)
- License Agreement by and between Yumanity Therapeutics, Inc. and MIL 40, LLC dated as of February 28, 2022 (Filed With SEC on March 4, 2022)
- License Agreement, by and between Yumanity Therapeutics, Inc. and MIL 40G LLC, dated as of February 5, 2020 (Filed With SEC on September 23, 2020)
- Tangible Property and Exclusive Patent License Agreement, by and between Yumanity Therapeutics, Inc., Yumanity Holdings, LLC and Whitehead Institute for Biomedical Research, dated... (Filed With SEC on September 23, 2020)
- Technology Transfer and License Agreement between the Company and Genentech, Inc., dated December 13, 2018 (Filed With SEC on March 8, 2019)
- COLLABORATIVE RESEARCH, DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT BY AND BETWEEN PROTEOSTASIS THERAPEUTICS, INC. and BIOGEN IDEC NEWVENTURES INC. December 5, 2013 (Filed With SEC on December 23, 2015)
- AMENDED AND RESTATED LICENSE AGREEMENT (Filed With SEC on December 23, 2015)
